CASI Pharmaceuticals (CASIF) Other Non-Current Assets (2021 - 2025)

CASI Pharmaceuticals has reported Other Non-Current Assets for 5 years, with the latest figure at $740000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Assets rose 26.06% year-over-year to $740000.0; the trailing twelve-month figure through Dec 2025 stood at $740000.0 (up 26.06% YoY), and the FY2025 full-year result was $740000.0, up 26.06% from the prior year.
• Other Non-Current Assets for Q4 2025 stood at $740000.0, up from $660000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.2 billion in Q2 2023, with the low at $587000.0 in Q4 2024.
• Historically, Other Non-Current Assets has averaged $296.5 million across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 99.92% — and 2025, when it surged 83945.58%.
• CASI Pharmaceuticals' Other Non-Current Assets stood at $2.2 million in 2021, then tumbled by 51.52% to $1.1 million in 2022, then soared by 72437.88% to $766.0 million in 2023, then tumbled by 99.92% to $587000.0 in 2024, then increased by 26.06% to $740000.0 in 2025.
• The last three Other Non-Current Assets figures came in at $740000.0 (Q4 2025), $660000.0 (Q3 2025), and $644000.0 (Q2 2025), per Business Quant data.